IPHA vs IRD

Innate Pharma S.A. vs Opus Genetics, Inc. — Valuation Comparison 2026

IPHA

Biotechnology
Innate Pharma S.A.
Quality
4.8
out of 10
Value Trap
26
LOW
Price
$1.74
Last close
Models
8/13
Active
VS

IRD

Biotechnology
Opus Genetics, Inc.
Quality
5.2
out of 10
Value Trap
44
WARN
Price
$4.20
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType IPHA Fair ValueIPHA Upside IRD Fair ValueIRD Upside
Bayesian DCF Intrinsic $0.54 -68.7% $1.10 -73.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.87 -49.9% $0.10 -98.0%
PWERM Option-Based $0.82 -53.0% $4.80 +14.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IPHA vs IRD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IPHA vs IRD — Which Stock Is More Undervalued?

IRD scores higher with a 5.2/10 quality rating vs IPHA's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Innate Pharma S.A. (IPHA) and Opus Genetics, Inc. (IRD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IPHA currently trades at $1.74 with a QOC of 4.8/10, while IRD trades at $4.20 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).